The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives...
After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...
LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...
Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI) remains a major clinical challenge. These...
Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...
Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...